References
- Noy A. Optimizing treatment of HIV-associated lymphoma. Blood. 2019;134(17):1385–1394.
- Gibson TM, Morton LM, Shiels MS, et al. Risk of non-Hodgkin lymphoma subtypes in HIV-infected people during the HAART era: a population-based study. AIDS. 2014;28(15):2313–2318.
- Re A, Cattaneo C, Rossi G. Hiv and lymphoma: from epidemiology to clinical management. Mediterr J Hematol Infect Dis. 2019;11(1):e2019004.
- Lewden C, May T, Rosenthal E, ANRS EN19 Mortalité Study Group and Mortavic1, et al. Changes in causes of death among adults infected by HIV between 2000 and 2005: the “ "Mortalité 2000 and 2005" surveys (ANRS EN19 and Mortavic)”. J Acquir Immune Defic Syndr. 2008;48(5):590–598.
- Smith CJ, Ryom L, Weber R, D:A:D Study Group, et al. Trends in underlying causes of death in people with HIV from 1999 to 2011 (D:A:D): a multicohort collaboration. Lancet. 2014;384(9939):241–248.
- Vase MØ, Ludvigsen M, Bendix K, et al. Proteomic profiling of pretreatment serum from HIV-infected patients identifies candidate markers predictive of lymphoma development. AIDS. 2016;30(12):1889–1898.
- Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the world health organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375–2390.
- Hybel TE, Vase MØ, Maksten EF, et al. Intratumoral expression of CD38 in patients with post-transplant lymphoproliferative disorder. Acta Oncol (Madr) [Internet]. 2021; 60:1–6. https://doi.org/10.1080/0284186X.2021.1973093
- Hoffmann C, Tiemann M, Schrader C, et al. AIDS-related B-cell lymphoma (ARL): correlation of prognosis with differentiation profiles assessed by immunophenotyping. Blood. 2005;106(5):1762–1769.
- Koizumi Y, Uehira T, Ota Y, et al. Clinical and pathological aspects of human immunodeficiency virus-associated plasmablastic lymphoma: analysis of 24 cases. Int J Hematol. 2016;104(6):669–681.
- Calabretta E, Carlo-Stella C. The many facets of CD38 in lymphoma: from Tumor-Microenvironment cell interactions to acquired resistance to. Immunotherapy. Cells. 2020;9(4):802.
- Savarino A, Bottarel F, Malavasi F, et al. Role of CD38 in HIV-1 infection: an epiphenomenon of T-cell activation or an active player in virus/host interactions? AIDS. England. 2000;14:1079–1089.
- Giorgi JV, Hultin LE, McKeating JA, et al. Shorter survival in advanced human immunodeficiency virus type 1 infection is more closely associated with T lymphocyte activation than with plasma virus burden or virus chemokine coreceptor usage. J Infect Dis. 1999;179(4):859–870.
- D’Agostino M, Innorcia S, Boccadoro M, et al. Monoclonal antibodies to treat multiple myeloma: a dream come true. Int J Mol Sci. 2020;21:21.
- Tan CR, Barta SK, Lensing SY, et al. A multicenter, Open-Label feasibility study of daratumumab with Dose-Adjusted EPOCH in newly diagnosed plasmablastic lymphoma: AIDS malignancy consortium 105. Blood [Internet]. 2019;134(Supplement_1):1595–1595. https://doi.org/10.1182/blood-2019-129702